Diltiazem ER — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Atrial fibrillation

• Digoxin
• Metoprolol tartrate
• Warfarin

Also listed for High Blood Pressure

• Amlodipine
• Lisinopril
• Losartan
• Atenolol
• Hydrochlorothiazide

About Diltiazem ER

Diltiazem ER is a widely prescribed medication crucial for managing various heart conditions, from high blood pressure to certain types of chest pain. For those relying on this vital prescription, managing costs can be a significant concern. TheDrugClub is dedicated to making essential medications like Diltiazem ER accessible and affordable, offering substantial savings to our members.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Diltiazem ER is approved for (FDA label)

Diltiazem hydrochloride extended-release capsules are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. Diltiazem hydrochloride extended-release capsules are indicated for the management of chronic stable angina and angina due to coronary artery spasm.

Source: Read the full FDA label on DailyMed. Label effective date: August 27, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Diltiazem ER (FDA label)

Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded from these studies. The following table presents the most common adverse reactions reported in placebo-controlled angina and hypertension trials in patients receiving diltiazem hydrochloride extended-release capsules up to 360 mg with rates in placebo patients shown for comparison. In addition, the following events were reported infrequently (less than 1%) in angina or hypertension trials: Cardiovascular: Congestive heart failure, palpitations, syncope, ventricular extrasystoles. Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, hallucinations, insomnia, nervousness, paresthesia, personality change, somnolence, tinnitus, tremor.

Source: FDA prescribing information (DailyMed). Set ID: 5a0f67ad-17d8-a3f4-e063-6394a90afb32. SPL document ID: 5a0f57a6-50c2-e1f4-e063-6294a90a614d. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Diltiazem ER (FDA label)

Diltiazem hydrochloride extended-release capsules are contraindicated in (1) patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker, (2) patients with second- or third-degree AV block except in the presence of a functioning ventricular pacemaker, (3) patients with hypotension (less than 90 mm Hg systolic), (4) patients who have demonstrated hypersensitivity to the drug, and (5) patients with acute myocardial infarction and pulmonary congestion documented by x-ray on admission.

Source: FDA prescribing information (DailyMed). Set ID: 5a0f67ad-17d8-a3f4-e063-6394a90afb32. SPL document ID: 5a0f57a6-50c2-e1f4-e063-6294a90a614d. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Diltiazem ER (FDA label)

Because of the potential for additive effects, slow titration is warranted in patients receiving diltiazem hydrochloride concomitantly with other agents known to affect cardiac contractility and/or conduction (see WARNINGS ). Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with diltiazem hydrochloride extended-release capsules (see WARNINGS ). Diltiazem is both a substrate and an inhibitor of the Pg-p and cytochrome P450 3A4 enzyme system which may affect exposure to diltiazem and concomitant drugs metabolized by those pathways. Patients with renal and/or hepatic impairment may be particularly at risk of exposure changes. Anesthetics : The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers. When used concomitantly, titrate anesthetics and calcium blockers slowly.

Source: FDA prescribing information (DailyMed). Set ID: 5a0f67ad-17d8-a3f4-e063-6394a90afb32. SPL document ID: 5a0f57a6-50c2-e1f4-e063-6294a90a614d. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.